Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Novamind’s Trial Site for Merck Another Example Of Its Leadership in Mental Health

Novamind’s clinics and clinical research capabilities are already well established to bring alternative mental health therapies, including psychedelic medicine, to market. One of the world’s largest pharmaceutical companies has selected ...
Featured Submission | March 24, 2021 |

Clinical research and tools to address mental health

Our next company is Numinus Wellness Inc. (TSX:NUMI) . Numinus is using the power of psychedelic medicine to make great strides in addressing serious mental health issues. It recently announced its fiscal year 2024 results, which showed strong growth in its busines...
Ryan Dhillon | December 14, 2023 |

The Revolutionary Co. That’s Breaking Through the Blood Brain Barrier

(Click image to play video) Delivery of therapeutics across the blood-brain barrier (BBB) and into the brain has been the single greatest challenge to treating hundreds of common and rare neurological diseases, including brain cancers, neurodegenerative diseases...
Dave Jackson | December 1, 2020 |

Buzz on the Bullboards: Who is shining through the market slump?

The market story this week has been less impressive on both sides of the border than what we saw in the week where February turned to March. Recent losses and flatline trading have negated Wall Street’s previous record-setting run where major U.S. indices ...
Jonathon Brown | March 7, 2024 |

Shortcomings of Traditional IT MSPs In The Mining Industry

Each and every one of us benefits from the contents that are extracted from a mine. As the world population continues to grow, it creates enormous pressure on mining companies to supply the minerals, metal and fuel that we have all become dependent on to improve our quality ...
Lloyd Ainey | September 17, 2020 |

Stockhouse Media Alert: Podcasts from XFUTURE 2019

The Extraordinary Future Conference attracted more than 2,500 attendees to the Vancouver Convention Centre to gain insight from high-profile speakers and analysts on all things emerging from the cannabis and tech sector. And Stockhouse Media covered the event LI...
Stockhouse Media | September 23, 2019 |

Buzz on the Bullboards: The Next Pot of Gold in 2022?

(Photo of mineralization from NFGC-21-195 approximately 285m down hole depth and Right: NFGC-21-202 approximately 146m down hole depth. Image via New Found Gold Corp.) We have waited three long years for this: St. Patrick’s Day is back, and so are al...
Stockhouse Editorial | March 15, 2022 |

Regeneron Shares Rise 10% on Advances in its Novel COVID-19 Antibody Program

Shares of Regeneron Pharmaceuticals rose to a new 52-week high price after the company reported it has identified hundreds of virus-neutralizing antibodies and plans to initiate large-scale manufacturing by mid-April of a multi-antibody therapy to treat coronavirus. ...
Streetwise Reports | March 18, 2020 |

Bringing Hope to People Living with Neurodegenerative Diseases

Alpha Cognition Inc. ( TSX-V.ACOG , OTCMKTS: ACOGF , Forum ) is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases. Stockhouse Media’s Dave Jackson caught up recently with Company CE...
Dave Jackson | October 20, 2021 |

Unique Value-Added Antiviral Vaccine Technology Platform

(Click to play video.) Founded in 2018 to improve on protein haptenization and leverage previous vaccine development in the field, Vancouver, BC-based BioVaxys Technology Corp . ( CSE.BIOV , OTCQB: BVAX , Forum ) is a clinical stage biotechnology company that...
Dave Jackson | September 14, 2021 |
1 2 3 4 5 6 7 8 9 10 ...